Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder

Objectives: To evaluate the short-term efficacy and safety of desvenlafaxine (25–50 mg/d) compared with placebo in children and adolescents with major depressive disorder (MDD). Methods: Outpatient children (7–11 years) and adolescents (12–17 years) who met DSM-IV-TR criteria for MDD and had screeni...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Child Adolesc Psychopharmacol
Hoofdauteurs: Weihs, Karen L., Murphy, William, Abbas, Richat, Chiles, Deborah, England, Richard D., Ramaker, Sara, Wajsbrot, Dalia B.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Mary Ann Liebert, Inc. 2018
Onderwerpen:
Original Articles
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5771543/
https://ncbi.nlm.nih.gov/pubmed/29189044
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/cap.2017.0100
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items